A key metric for policy makers in the fight against COVID-19

In episode two of our fortnightly COVID-19 webinar series, healthcare sector head, Dr Nick Cameron outlines a key metric that policy makers will consider when deciding if COVID-19 containment measures should be lifted.

This webinar was recorded on 9 April, 2020. To view the full webinar, including comprehensive insights from the Antipodes team on its approach to investing in current global markets, click here.

You can register for upcoming webinars in the series here.

 

Episode 2 Part 1 – Transcript:

Dr Nick Cameron:

When we’re waiting for a vaccine and waiting to find if drugs work and the curve is flatting, governments are stuck with the decision of whether to keep social distancing and restrictions in place. Until we have a vaccine – which is the ultimate remedy for the situation and provides ultimate confidence for governments (to take the chains off the economy) and for people – I think we really need to consider the healthcare system’s capacity or ability to be able to deal with the severely affected patients and that is particularly looking at ICU’s.

So, whether or not this virus is a seasonal virus, or whether indeed early relaxation of restrictions sees another wave coming, the ICU and ventilator capacity will be the key metric that policy makers will consider when they’re looking to lift restrictions. For example, we’ve taken a look at some of the major geographies across the world and their capacity (or ICU beds), and what we’ve done – represented in the chart below (see slide 4) – is run a scenario and basically made some key assumptions:

  1. We assume all ICU beds now are 50% available. That assumption is based on, at any one point in time, there’ll be car accidents, trauma, multiple critically ill patients that will need ICU anyway, as an underlying, let’s call it “baseline” activity. And through the actions of healthcare providers and hospital operators, they’ve been able to free up a bit of capacity as well from elective surgeries. So we arrive at a fairly broad assumption that 50% of beds are currently available for ICU COVID patients.
  2. Based on Chinese data and also experience from other geographies, including the US, it appears as though roughly 5% of COVID cases may require an ICU visit or ventilation.

So, using these assumptions we have a look at what the current case load is in some of these countries and you can see in the dark bar, this is the current number of ICU beds available per 100,000 people. Next to it, in the orange, you can see these are the potential cases, based on the current number of cases and 5% of them requiring ICU.

What you can see is that in some of the European countries, particularly Italy, France and Spain, that there is quite a shortage there and there is a clear direct link between the capacity to treat these patients in ICUs and the case to fatality rate.

The good news story is that the curve is flattening, and growth rates are slowing in some of these countries, in particular Italy, and so some of the pressure on the system may abate. But what’s not clear and what is not represented in this case is just how much capacity has been added quickly and then also what the potential second wave may look like and how severe it is. 

View the full webinar


This communication was prepared by Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) (Antipodes). Antipodes believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distribution and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so in light of their specific investment objectives and financial situations. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws, Antipodes disclaim all liability to any person relying on the information contained on this website in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.
Any opinions or forecasts reflect the judgment and assumptions of Antipodes on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and may not be realised in the future. Information on this website is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained on the website is prohibited without obtaining prior written permission from Antipodes.
Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 is the product issuer of funds managed by Antipodes.  Any potential investor should consider the relevant Product Disclosure Statement available at www.antipodesonespartners.com when deciding whether to acquire, or continue to hold units in a fund. The issuer is not licensed to provide financial product advice.  Please consult your financial adviser before making a decision. Past performance is not a reliable indicator of future performance.
9 April 2020
Antipodes